ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025
Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Risk Adjustment in the Medicare Advantage Population Using Encounter Data.Health services research · 2026Article
- Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage and Traditional Medicare.JAMA internal medicine · 2026Article
- Palliative Care for Advanced Cancer in Medicare Advantage and Physician Networks.JAMA network open · 2026Article
- Inpatient and Postacute Care After Head and Neck Surgery Among Beneficiaries.Laryngoscope investigative otolaryngology · 2026Article
- Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer.JAMA network open · 2026Article
- Provider billing margin and cancer treatment selection: population based cohort study.BMJ (Clinical research ed.) · 2025Article
- Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.JAMA network open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeMedicare Advantage (MA) provides beneficiaries an option to receive Medicare benefits from private plans. Although MA covers over half of the Medicare population, limited information exists about how utilization of cancer treatments in MA differs from traditional Medicare (TM). We compared use of low-value cancer treatments between MA and TM and analyzed variation in use of low-value cancer treatments across large MA insurers.
methodsUsing national Medicare data, we performed retrospective analyses of beneficiaries who had a new cancer diagnosis between 2016 and 2021 and who were at risk of receiving a low-value treatment: granulocyte-colony stimulating factors (GCSFs) for patients receiving low-risk chemotherapy, denosumab for castration-sensitive prostate cancer (CSPC), nab-paclitaxel instead of paclitaxel for breast or lung cancers, adding bevacizumab to carboplatin plus paclitaxel for ovarian cancer, and branded drugs or biologics for which generic or biosimilar versions existed.
resultsUse of any low-value cancer treatment was 1.7 percentage points lower in MA than in TM (34.2%
conclusionMA has lower use of low-value cancer treatments than TM, with varying degrees across large MA insurers. Efforts are needed to identify effective strategies to reduce use of low-value cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.